GoldenGolden
Advanced Search
Glycostem

Glycostem

Glycostem is a biotechnology developing cellular immunotherapies.

All edits

Edits on 6 Aug, 2021
Golden AI"Inferring industry - ai.industry_clf.02"
Golden AI edited on 6 Aug, 2021
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 14 Jun, 2021
Erin Scherfner"prospector:324:159659"
Erin Scherfner edited on 14 Jun, 2021
Edits made to:
Infobox (+2 properties)
Infobox
Edits on 23 Feb, 2021
Golden AI"Setting founded date to the company's date of incorporation."
Golden AI edited on 23 Feb, 2021
Edits made to:
Infobox (+1 properties)
Infobox
Founded date
2007
Edits on 20 Nov, 2020
Henry Ogolla
Henry Ogolla edited on 20 Nov, 2020
Edits made to:
Timeline (+1 events) (+132 characters)
Timeline

November 20, 2020

Glycostem Therapeutics announces the opening of a phase I/IIa trial for its lead product oNKord® for the treatment of AML patients.
Edits on 25 Apr, 2019
Golden AI
Golden AI edited on 25 Apr, 2019
Edits made to:
Infobox (+1 properties)
Infobox
Industry
Edits on 13 Mar, 2019
Dawson Sewell
Dawson Sewell edited on 13 Mar, 2019
Edits made to:
Description (-13 characters)
Topic thumbnail

Glycostem Therapeutics Glycostem

Glycostem Therapeutics is a biotechnology developing cellular immunotherapies.

Dawson Sewell
Dawson Sewell edited on 13 Mar, 2019
Edits made to:
Infobox (+8 properties)
Description (+79 characters)
People (+4 rows) (+8 cells) (+68 characters)
Categories (+2 topics)
Related Topics (+1 topics)
Topic thumbnail

Glycostem Glycostem Therapeutics

Glycostem Therapeutics is a biotechnology developing cellular immunotherapies.

People

Name
Role
Related Golden topics

Hareth Nahi

CMO

Jan Spanholtz

CSO

Troels Jordansen

CEO

Volker Huppert

COO

Infobox
Industry
Location
Date incorporated
2007
Categories
Related Topics
Dawson Sewell"Initial topic creation"
Dawson Sewell created this topic on 13 Mar, 2019
Edits made to:
Topic thumbnail

 Glycostem

Glycostem is a biotechnology developing cellular immunotherapies.

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.